Iroko Pharmaceuticals Comments on Joint FDA Advisory Committee Meeting on NSAIDs

13-02-2014 Business Wire HealthComments (0)

BiotechnologyInflammatory diseasesPharmaceuticalUSA

On February 10 and 11, 2014, the US Food and Drug Administration (FDA) Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) discussed data and analyses published post 2005 that are relevant to further understanding the relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular thrombotic risk that is currently described in NSAID class labeling. Iroko addressed the pa

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top